# Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus

> **NCT03585530** · PHASE2 · UNKNOWN · sponsor: **Huai'an First People's Hospital** · enrollment: 32 (actual)

## Conditions studied

- Esophagus Squamous Cell Carcinoma

## Interventions

- **DRUG:** raltitrexed

## Key facts

- **NCT ID:** NCT03585530
- **Lead sponsor:** Huai'an First People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-05
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-03-15
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03585530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03585530, "Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03585530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*